These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 37296380

  • 1. Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis.
    Huang YL, Xu XZ, Liu J, Wang PY, Wang XL, Feng HL, Liu CJ, Han X.
    BMC Cardiovasc Disord; 2023 Jun 09; 23(1):293. PubMed ID: 37296380
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysis.
    de Wit HM, Te Groen M, Rovers MM, Tack CJ.
    Br J Clin Pharmacol; 2016 Jul 09; 82(1):301-14. PubMed ID: 26935973
    [Abstract] [Full Text] [Related]

  • 4. Sodium-glucose co-transporter-2 inhibitors and the risk of venous thromboembolism: A nationwide population-based study and meta-analysis.
    Tsai HR, Lin YJ, Yeh JI, Huang YC, Liu PP, Peng CC, Hsu JY, Lee YC, Loh CH, Lin SM, Huang HK.
    Diabetes Metab Res Rev; 2024 Feb 09; 40(2):e3739. PubMed ID: 37862117
    [Abstract] [Full Text] [Related]

  • 5. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.
    Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JM.
    Kidney Int; 2024 Mar 09; 105(3):618-628. PubMed ID: 38101515
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M, Dietrich JW, Nauck MA, Lim S.
    Cardiovasc Diabetol; 2023 Jun 28; 22(1):153. PubMed ID: 37381019
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom.
    Brunetti VC, St-Jean A, Dell'Aniello S, Fisher A, Yu OHY, Bugden SC, Daigle JM, Hu N, Alessi-Severini S, Shah BR, Ronksley PE, Lix LM, Ernst P, Filion KB, Canadian Network for Observational Drug Effect Studies (CNODES) Investigators.
    BMC Endocr Disord; 2022 Sep 29; 22(1):241. PubMed ID: 36175881
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L, Zheng XQ, Liao XX.
    Prim Care Diabetes; 2022 Feb 29; 16(1):207-210. PubMed ID: 34953749
    [Abstract] [Full Text] [Related]

  • 13. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies.
    Hidayat K, Du X, Shi BM.
    Osteoporos Int; 2019 Oct 29; 30(10):1923-1940. PubMed ID: 31134305
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
    Mishriky BM, Powell JR, Wittwer JA, Chu JX, Sewell KA, Wu Q, Cummings DM.
    Diabetes Obes Metab; 2019 Oct 29; 21(10):2274-2283. PubMed ID: 31168889
    [Abstract] [Full Text] [Related]

  • 16. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, Chang Y, Byrne CD, Shin JY.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2349856. PubMed ID: 38153732
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, Meeran K.
    JAMA; 2018 Apr 17; 319(15):1580-1591. PubMed ID: 29677303
    [Abstract] [Full Text] [Related]

  • 20. Effects of Antidiabetic Drugs on Endothelial Function in Patients With Type 2 Diabetes Mellitus: A Bayesian Network Meta-Analysis.
    Wang Y, Yao M, Wang J, Liu H, Zhang X, Zhao L, Hu X, Guan H, Lyu Z.
    Front Endocrinol (Lausanne); 2022 Apr 17; 13():818537. PubMed ID: 35370959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.